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ABSTRACT
Pancreatic cancer has a dismal prognosis particularly in patients presenting 
with unresectable tumors. We performed a bibliometric analysis of clinical trials for 
pancreatic cancer conducted between 2014-2016 focusing on patients that presented 
with unresectable (locally advanced or metastatic) tumors. We discuss a range of 
studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and 
studies that used molecularly-targeted therapy. Major areas of focus have been dual 
targeting of EGFR and VEGFR, immunotherapy or a multimodal approach – combining 
chemotherapy with radiotherapy. We also point out the need for molecular selection 
for low prevalence subtypes. Key insights sourced from these pivotal trials should 
improve clinical outcomes for this devastating cancer.
INTRODUCTION
The American Cancer Society reports increasing 
death rates for people who develop cancer of the 
pancreas, with a 5-year survival rate of only 8% [1]. 
Most recently global data, acquired as part of the 
GLOBOCAN project in 2012, revealed pancreatic 
cancer to be the 7th most common cause of cancer death, 
accounting for approximately 338000 cancer diagnoses 
and 331000 deaths. In Western societies, it is the 4th 
leading cause of cancer death, and recently overtook 
breast cancer to become the 3rd leading cause in the 
USA, and is projected to be the second leading cause 
within a decade [2]. These abysmal statistics are partly 
attributed to the fact that 53% of pancreatic cancers 
are diagnosed metastatic and 28% with loco-regional 
disease, with survival rates of 2% and 11%, respectively. 
As resection is the only curative therapy for pancreatic 
cancer patients, management is mainly confined to 
chemotherapy, which is sometimes combined with 
radiotherapy in loco-regional disease. Since our last 
review of therapeutic strategies for the treatment of 
pancreatic cancer [3], major advances have been made 
in therapies available to patients with locally advanced 
pancreatic cancer (LAPC) and metastatic pancreatic 
cancer (MPC). Here we examined the changing 
landscape of the clinical management of unresectable 
pancreatic adenocarcinomas (PDAC). Bibliometric 
analysis was also utilized to gauge the level of scientific 
interest in particular therapeutic strategies.
METHODS
For bibliometric analysis the PubMed database was 
queried using the “trial AND (pancreas OR pancreatic) 
AND (cancer OR tumor OR adenocarcinoma) AND 
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(unresectable OR advanced OR metastatic)” search 
term, specifying publication dates from 2014/01/01 
to 2016/12/31 to identify relevant articles published 
since 2014. Figure 1 provides a flowchart showing 
how bibliometric information was processed during 
the course of systematic review. Of the 615 identified 
articles, reviews, case-studies, sub-group analyses and 
meta-analyses were excluded. Reports that did not 
explore therapeutic strategies for the purpose of treating 
unresectable pancreatic ductal adenocarcinomas, i.e. 
ultimately increasing overall survival (OS) of patients, 
were also excluded, leaving 171 relevant articles. This 
included first-line and second-line studies, and dose-
finding studies performed in patients presenting with 
a broad grouping of advanced solid tumors as long as 
pancreatic cancer patients were included. Studies that 
primarily investigated prophylactic treatments were 
excluded. Phase I trials investigating therapeutics in 
multiple advanced solid tumor types were included in 
this systematic review but survival data was only used 
if pancreatic cancer data was reported. Citation data was 
retrieved from Web of Science.
STANDARD OF CARE
New standards of care have been established 
from two landmark phase III trials that demonstrated 
significant improvements in OS in patients that presented 
with metastatic pancreatic cancer. An overview of the 
clinical trials that have influenced this standard of care, 
outlining OS achieved using different drug combinations, 
is included in Table 1. In 2011, Conroy et al. (PRODIGE) 
[4] demonstrated that an OS of 11.1 months was achievable 
in chemotherapy-naïve patients treated with a combination 
of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin 
(FOLFIRINOX), compared to 6.8 months in patients treated 
with gemcitabine alone. Subsequently, Von Hoff et al. 
(MPACT) [5], also achieved a significant improvement in 
Figure 1: Flow chart depicting how bibliometric information was processed in the course of this review.
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OS in patients treated with gemcitabine and the stromal-
targeting nanoparticle albumin-bound paclitaxel (nab-
paclitaxel) (GNP) when compared with patients receiving 
gemcitabine monotherapy (8.5 vs 6.7 months).
Increased interest and adoption of the FOLFIRINOX 
combination and its variants, and the GNP combination 
are reflected in increases in the number of clinical 
trials that have employed these strategies over the last 
3 years (Figure 2). In fact, there was an increase in the 
use of fluoropyrimidine-based therapies, which includes 
5-fluorouracil, or its prodrugs capecitabine or tegafur in 
this same period. Gemcitabine-based therapies, including 
CO-101 – a lipid drug conjugate of gemcitabine – 
remained highly utilized in the treatment of PDAC. 
However, there was a decrease in the proportion of trials 
that employed gemcitabine-based therapies from 2015 to 
2016. There was also little change in the utilization of the 
gemcitabine/erlotinib combination, which although shown 
Table 1: Studies that influenced current standard of care, displayed in order of publication
OS Title Reference Patients Phase Randomization
5.65 months Gem, 4.41 
months 5-fluorouracil
Improvements 
in survival and 
clinical benefit with 
gemcitabine as first-
line therapy for patients 
with advanced pancreas 
cancer: a randomized 
trial.
Burris et al. J Clin 
Oncol. 1997
126 III Yes
6.24 months Gem + 
Erlotinib, 5.91 months 
Gem
Erlotinib plus 
gemcitabine compared 
with gemcitabine 
alone in patients with 
advanced pancreatic 
cancer: a phase III trial 
of the National Cancer 
Institute of Canada 
Clinical Trials Group.
Moore et al. J Clin 
Oncol. 2007
569 III Yes
11.1 months 
FOLFIRINOX, 6.8 
months Gem
FOLFIRINOX versus 
gemcitabine for 
metastatic pancreatic 
cancer.
Conroy et al. N Engl 
J Med. 2011
342 III Yes
8.5 months Gem + nab-
paclitaxel, 6.7 months 
Gem
Increased survival in 
pancreatic cancer with 
nab-paclitaxel plus 
gemcitabine.
Von Hoff et al. N 
Engl J Med. 2013
861 III Yes
6.1 months nano-
irinotecan + 
5-fluorouracil + folinic 
acid, 4.2 months 
5-fluorouracil + folinic 
acid
Nanoliposomal 
irinotecan with 
fluorouracil and folinic 
acid in metastatic 
pancreatic cancer after 
previous gemcitabine-
based therapy 
(NAPOLI-1): a global, 
randomised, open-
label, phase 3 trial
Wang-Gillam et al. 
Lancet 2016 (Epub 
2015)
417 III Yes
Median overall survival (OS) in advanced pancreatic cancer patients is significantly improved using the gemcitabine + 
nab-paclitaxel or FOLFIRINOX combinations when compared to the previous standard of care, gemcitabine (Gem). The 
addition of the targeted therapy, erlotinib, to conventional gemcitabine treatment had been shown to have a small but 
significant effect on OS in an earlier report. The combination of nanoliposomal irinotecan with 5-fluouracil and folinic acid 
has been FDA approved in the 2nd line setting.
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to significantly extend OS when compared to gemcitabine 
(6.24 months vs 5.91 months) [6], provided only a modest 
survival benefit.
While FOLFIRINOX may, on the surface, 
appear to outperform the GNP combination, we note 
that PRODIGE was a one country study with narrow 
scope, whereas MPACT was an international study that 
included older patients [median: 61 (range: 25-76) vs 
median: 63 (range: 27-88)] and those with a poorer 
performance status [1 patient (0.3%) with ECOG 
performance status > 1 vs 65 patients (7.6%) with 
Karnofsky performance status <80]. Both strategies 
were associated with adverse events including grade 
3 or higher neutropenia (45.7% vs 38%) and fatigue 
(23.6% vs 17%). Use of modified FOLFIRINOX, 
where irinotecan and bolus 5-fluorouracil is reduced 
by 25%, resulted in a significant reduction of grade 
3 or higher neutropenia (12.2%) and fatigue (12.2%) 
while achieving an OS of 10.2 months in patients with 
metastatic PDAC and 26.6 months in patients with 
LAPC [7]. This Phase II study was also conducted 
in a younger population [median: 62 (range: 50-
77)] with ECOG performance status scores <2. A 
meta-analysis conducted by Suker et al. [8] however, 
recently demonstrated the value of FOLFIRINOX in the 
treatment of LAPC with a median OS of 24.2 months 
in the pooled patient population. Proportion of patients 
that underwent surgery after FOLFIRINOX was 25.9% 
and R0 resection was achieved in 74% of these patients.
The GNP combination has also shown promise 
in the second-line setting in MPC patients refractory 
to FOLFIRINOX therapy [9], resulting in an OS of 8.8 
months or 18 months since the start of first-line therapy. 
This study included 12 patients (21%) with an ECOG 
performance status of 2, and 40% of patients reported 
grade 3 or higher adverse events, including neurotoxicity 
(12.5%) and neutropenia (12.5%).
Advancements that have followed from the 
success of the FOLFIRINOX combination include the 
development of nanoliposomal irinotecan (MM-398), 
designed to extend duration of the drug in the circulation, 
and preferential activation in the tumor. The highly 
cited findings of the NAPOLI-1 trial, which assessed 
nanoliposomal irinotecan in combination with 5-FU and 
folinic acid in MPC patients after failure of gemcitabine-
based therapy, achieved a significant improvement in 
OS compared to patients that received only 5-FU and 
folinic acid (6.1 months vs 4.2 months) [10]. As a result, 
this regimen became the first FDA approved second-line 
therapy (after gemcitabine failure) in patients that present 
with MPC. A Phase II trial investigating nanoliposomal 
irinotecan-based combinations in the first-line setting is 
underway [11].
It is important to note that US treatment guidelines 
recommend that patients that present with unresectable 
pancreatic cancer, particularly those with a good 
performance status, receive treatment within a clinical trial 
[12]. However, a 2013 study reported that only 4.57% of 
pancreatic cancer patients enroll into clinical trials [13] - a 
statistic that could be improved with greater awareness of 
pancreatic cancer trials and improved discussion between 
patients and caregivers [14].
Figure 2: Proportion of studies in 2014-2016 that employed conventional chemotherapies. Gemcitabine- and fluoropyrimidine-
based therapies were highly utilized in clinical trials, with increases seen in the employment of the latter over these 3 years. There were also 
increases in the utilization of the FOLFIRINOX and gemcitabine+nab-paclitaxel combinations in the same time period.
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In summary, all studies have shown incremental 
benefit only, with the choice between the 2 standards of 
care currently available (FOLFIRINOX and Gemcitabine 
+ nab-Paclitaxel) only based on performance status as no 
predictive patient selection tools currently exist.
MOLECULARLY-TARGETED THERAPY
Pancreatic tumors tend to be heterogeneous, 
presenting a challenge for treatment [9, 15, 16]. 
Molecularly-targeted therapies offer physicians the 
opportunity to tailor a strategy to the unique properties of 
a patient’s individual tumor. Further by selecting targets 
restricted to cancer or cancer-associated cells, and not 
healthy cells, these therapies potentially minimize side 
effects associated with conventional chemotherapeutic 
strategies that employ cytotoxic agents.
A molecularly-targeted therapy was explored in 
97 (54%) of the 178 clinical studies that investigated 
therapeutic strategies in patients presenting with 
unresectable pancreatic cancer (Figure 3). When dose-
finding studies were excluded, 63 studies (49%) of the 
remaining 129 studies employed molecularly-targeted 
therapy. Many of the most cited reports published in 
2014–2016 (Tables 2–4) investigated a molecularly-
targeted therapy.
Epidermal growth factor receptor (EGFR) or HER1, 
which resides on the surface of the cancer cell, remained 
the most utilized target, accounting for 27 (15%) of the 
178 trials in our review. The specific EGFR inhibitors, 
erlotinib, and cetuximab, accounted for 16 and 7 of 
these trials, respectively. A Phase II trial where LAPC 
patients that responded to gemcitabine/capecitabine 
therapy were randomized to receive radiotherapy, and a 
fluoropyrimidine-based therapy (capecitabine or uracil/
tegafur plus leucovorin), reported a non-significant 
increase in the OS achieved in patients that also received 
cetuximab (22 months vs 15.8 months) [17]. Further, 
patients with low baseline circulating miR-21 had an 
OS of 15.3 months, compared to 5.1 months in patients 
with high miR-21 levels in plasma (also not significant). 
Low enrolment numbers (17 patients, 13 analyzed) may 
account for a lack of statistical power.
Other EGFR-targeted therapeutics (panitimumab, 
afatinib, lapatinib and vandetanib) and the HER2 inhibitor, 
trastuzumab, were each used in just one study. A Phase 
I dose finding study that added the EGFR inhibitor 
panitimumab to gemcitabine-based chemoradiation in 
LAPC patients, appears promising, reporting an OS of 
12.3 months (19.5, 17 and 9.1 months at dose rates of 1, 
1.5 and 2 mg/kg, respectively) [18]. Combined inhibition 
of EGFR and HER2 using cetuximab and trastuzumab, 
in patients with gemcitabine-refractory MPC, resulted 
in an OS of 4.6 months [19]. Another Phase II trial [20] 
employing EGFR/HER2 tyrosine kinase inhibitor (TKI), 
lapatinib, in combination with capecitabine as second-
Figure 3: Proportion of studies in 2014-2016 that employed molecularly-targeted chemotherapies. Data is displayed in the 
order of the popularity of the target (the proportion of studies that utilized an inhibitor of that target). Molecularly targeted therapies were 
used in the majority of clinical trials investigating therapeutics in advanced pancreatic cancer patients in this timeframe.
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Table 2: Top cited articles published in 2014, 2015, and 2016 ranked by the number of citations (online publication 
or e-publication date used as date of publication)
Citations Title Reference Patients Phase Randomization
116 Second-line oxaliplatin, folinic acid, 
and fluorouracil versus folinic acid and 
fluorouracil alone for gemcitabine-
refractory pancreatic cancer: outcomes 
from the CONKO-003 trial
Oettle et al.
J Clin Oncol. 2014
168 III Yes
79 Gemcitabine and capecitabine with or 
without telomerase peptide vaccine 
GV1001 in patients with locally advanced 
or metastatic pancreatic cancer (TeloVac): 
an open-label, randomised, phase 3 trial
Middleton et al. Lancet 
Oncol. 2014
1062 III Yes
71 Phase 2 multi-institutional trial evaluating 
gemcitabine and stereotactic body 
radiotherapy for patients with locally 
advanced unresectable pancreatic 
adenocarcinoma
Herman et al. Cancer. 
2015
49 II No
138 Safety and survival with GVAX pancreas 
prime and Listeria Monocytogenes-
expressing mesothelin (CRS-207) boost 
vaccines for metastatic pancreatic cancer
Le et al. J Clin Oncol 
2015
90 II Yes
114 Nanoliposomal irinotecan with fluorouracil 
and folinic acid in metastatic pancreatic 
cancer after previous gemcitabine-
based therapy (NAPOLI-1): a global, 
randomised, open-label, phase 3 trial
Wang-Gillam et al. 
Lancet 2016 (Epub 
2015)
417 III Yes
81 Metformin in patients with advanced 
pancreatic cancer: a double-blind, 
randomised, placebo-controlled phase 2 
trial
Kordes et al. Lancet 
Oncol 2015
121 II Yes
77 Effect of Chemoradiotherapy vs 
Chemotherapy on Survival in Patients 
With Locally Advanced Pancreatic Cancer 
Controlled After 4 Months of Gemcitabine 
With or Without Erlotinib: The LAP07 
Randomized Clinical Trial
Hammel et al. JAMA 
2016
449 III Yes
46 Targeting tumour-associated macrophages 
with CCR2 inhibition in combination with 
FOLFIRINOX in patients with borderline 
resectable and locally advanced pancreatic 
cancer: a single-centre, open-label, dose-
finding, non-randomised, phase 1b trial
Nywening et al. Lancet 
Oncol 2016
47 Ib No
18 Final analysis of a phase II study of 
modified FOLFIRINOX in locally 
advanced and metastatic pancreatic cancer
Stein et al. Br J Cancer 
2016
75 II No
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line therapy in patients with gemcitabine-refractory MPC 
reported an OS of 5.2 months. However, the discrepancy 
in OS achieved in patients that responded with stable 
disease (8.3 months) vs progressive disease (2.9 months) 
suggests tumor-specific responses that may benefit from 
biomarker-based patient stratification.
Twenty four studies (13%) employed an inhibitor 
of vascular endothelial growth factor (VEGF) or platelet-
derived growth factor (PDGF), including 14 studies that 
employed a tyrosine kinase inhibitor (TKI). The VEGFA 
inhibitor bevacizumab was the most utilized inhibitor of 
angiogenesis pathways, and was employed in 6 studies 
(3%), and was used in combination with an EGFR inhibitor 
(erlotinib or cetuximab) in 4 of these studies. In fact, the 
addition of the bevacizumab/cetuximab combination 
improved clinical outcomes in patients presenting with 
LAPC and MPC (OS: 13 months) when compared with 
patients receiving conventional chemotherapy (OS: 7 
Table 3: Top 8 articles investigating therapies in patients that present with metastatic pancreatic cancer (MPC), 
ranked according to overall survival (OS)
OS Title Reference Patients Phase Randomization
717 days (strong 
DTH reactions)
Treatment with chemotherapy 
and dendritic cells pulsed 
with multiple Wilms’ tumor 
1 (WT1)-specific MHC class 
I/II-restricted epitopes for 
pancreatic cancer
Koido et al. Clin 
Cancer Res. 2014
10 I No
18 months, 8.1 
months after first-line 
therapy
Nab-paclitaxel plus 
gemcitabine for metastatic 
pancreatic adenocarcinoma 
after Folfirinox failure: 
an AGEO prospective 
multicentre cohort
Portal et al. Br J 
Cancer 2015
57 II No
13.5 months Phase I/II study of nab-
paclitaxel plus gemcitabine 
for chemotherapy-naive 
Japanese patients with 
metastatic pancreatic cancer
Ueno et al. Cancer 
Chemother 
Pharmacol 2016
34 I/II No
13.5 months fluoro 
after GNP, 9.5 
months fluoro after 
Gem
Second-line therapy 
after nab-paclitaxel plus 
gemcitabine or after 
gemcitabine for patients with 
metastatic pancreatic cancer
Chiorean et al. Br J 
Cancer 2016
347 retrospective
11.9 months 
GEMOXEL, 7.1 
months Gem
Gemcitabine, oxaliplatin, and 
capecitabine (GEMOXEL) 
compared with gemcitabine 
alone in metastatic pancreatic 
cancer: a randomized phase 
II study
Petrioli et al. 
Cancer Chemother 
Pharmacol 2015
67 II Yes
11 months FIRGEM, 
8.2 months Gem
Fixed-dose rate gemcitabine 
alone or alternating with 
FOLFIRI3 (irinotecan, 
leucovorin and fluorouracil) 
in the first-line treatment 
of patients with metastatic 
pancreatic adenocarcinoma: 
an AGEO randomised phase 
II study (FIRGEM)
Trouilloud et al. 
Eur J Cancer 2014
98 II Yes
Gem indicates gemcitabine, fluoro indicates fluoropyrimidine-based therapy, GNP indicates gemcitabine+nab-paclitaxel, 
DTH indicates delayed-type hypersensitivity.
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months) [21]. The addition of the targeted bevacizumab/
erlotinib combination to the gemcitabine/capecitabine 
chemotherapy combination achieved an OS of 12.6 
months (10.1 months in MPC patients) [22]. Further, an 
OS of 17.4 months was achieved in a trial where LAPC 
patients were treated with capecitabine, erlotinib, and 
bevacizumab with concurrent radiotherapy [23].
TKIs were employed in 17 (10%) studies included in 
this review. Sorafenib, a TKI of VEGFR, PDGFR and Raf, 
was utilized in 5 studies (3%). One of these studies [24], 
a Phase I trial treating LAPC patients with a combination 
of gemcitabine and sorafenib, with concurrent radiation 
therapy, achieved an OS of 12.6 months. Another Phase 
I trial [25] investigating the gemcitabine/sorafenib 
combination in patients that presented with LAPC 
and MPC, linked serum levels of an indirect marker of 
angiogenesis (lactate dehydrogenase) with response to 
chemotherapy containing sorafenib.
Table 4: Top 8 articles investigating therapies in patients that present with locally advanced pancreatic cancer 
(LAPC), ranked according to median overall survival (OS) achieved
OS Title Reference Patients Phase Randomization R0 resection
29 months (arterial 
involvement), 42+ 
months (venous 
involvement)
Neoadjuvant 
gemcitabine, 
docetaxel, and 
capecitabine followed 
by gemcitabine and 
capecitabine/radiation 
therapy and surgery 
in locally advanced, 
unresectable pancreatic 
adenocarcinoma
Sherman et al. 
Cancer 2015
45 III No 67% (arterial 
involvement), 
73% (venous 
involvement)
26.6 months in LAPC Final analysis of a phase 
II study of modified 
FOLFIRINOX in locally 
advanced and metastatic 
pancreatic cancer
Stein et al. Br J 
Cancer 2016
75 II No 41.9%
12.3 months in all 
treated patients, 19.5 
months with a dose of 
1 mg/kg
Phase I Clinical Trial to 
Determine the Feasibility 
and Maximum Tolerated 
Dose of Panitumumab to 
Standard Gemcitabine-
Based Chemoradiation 
in Locally Advanced 
Pancreatic Cancer
Van Zweeden et 
al. Clin Cancer 
Res 2015
14 I No Not 
determined
18.8 months Baseline metabolic 
tumor volume and total 
lesion glycolysis are 
associated with survival 
outcomes in patients 
with locally advanced 
pancreatic cancer 
receiving stereotactic 
body radiation therapy
Dholakia et 
al. Int J Radiat 
Oncol Biol Phys 
2014
32 II No Not 
determined
18.4 months LAPC, 
14.4 months BRPC
The Role of Stereotactic 
Body Radiation Therapy 
for Pancreatic Cancer: 
A Single-Institution 
Experience.
Moningi et al. 
Ann Surg Oncol. 
2015
88 (74 
LAPC)
No 84% margin 
negative, 16% 
pathologic 
complete 
response
CRT indicates chemoradiotherapy, IC indicates induction chemotherapy, and BRPC indicates borderline resectable 
pancreatic cancer. Rates of achieving microscopic tumor clearance (R0) with resections are also displayed.
Oncotarget21621www.oncotarget.com
The Ras/Raf/MEK pathway was targeted in 13 (7%) 
of trials included in this review. A randomized Phase II trial 
evaluating gemcitabine combined with trametinib, an oral 
MEK inhibitor in patients that presented with MPC showed 
no statistically significant improvement in OS compared to 
the gemcitabine + placebo control (8.4 months vs 6.7 months) 
[26]. A Phase II/III trial of a combination of gemcitabine with 
rigosertib, a Ras mimetic and small molecule inhibitor of 
PLK1 and PI3K, also showed no significant survival benefit 
when compared with gemcitabine in patients that present 
with MPC (6.1 months vs 6.4 months) [27]. A Phase II trial of 
the MEK1/2 inhibitor, selumetinib, delivered in combination 
with erlotinib, in the second-line setting, achieved an OS of 
7.3 months [28].
Studies that targeted the PI3K/AKT/mTOR 
pathway accounted for 7 (4%) of trials included in 
this review. Of these, the most significant was a Phase 
II study of the oral mTOR inhibitor, everolimus, in 
combination with capecitabine achieved an OS of 
8.9 months in patients that presented with advanced 
pancreatic cancer (94% MPC) [29].
Six (3%) studies employed an IGF1R inhibitor. A 
Phase III trial of ganitumab, a monoclonal antibody against 
IGF1R, delivered in combination with gemcitabine, failed 
to demonstrate a survival benefit in MPC patients when 
compared to gemcitabine alone [7.0 months (gemcitabine 
+ 12 mg/kg ganitumab), 7.1 months (gemcitabine + 20 mg/
kg ganitumab), 7.2 months (gemcitabine + placebo)] [30]. 
A Phase I study of somastatin analog and IGF1R inhibitor, 
pasireotide, achieved an OS of 6.9 months in LAPC and 
MPC patients [31]. Dual targeting of EGFR and IGF1R 
using erlotinib and cixutumumab did not enhance the 
efficacy of gemcitabine anymore than erlotinib alone [6.7 
months (gemcitabine + erlotinib + cixutumumab) vs 7.0 
months (gemcitabine + erlotinib)] [32].
Hedgehog signaling elements (hedgehog/smo/γ 
secretase) accounted for 5 (3%) of studies included in our 
dataset. Interest in this signaling pathway stems from its 
roles in pancreatic cancer stem cell maintenance and, as 
it is expressed by stromal cells, tumor hypoxia. However, 
clinical trials that targeted hedgehog elements failed to 
demonstrate survival benefits [33–35].
Our analysis indicated a slight decline in the 
percentage of clinical trials that employed targeted 
therapies from 2014 to 2015, and again from 2015 to 
2016. Speculatively, this may be indicative of increased 
interest in improving FOLFIRINOX- and GNP-based 
combinations, stemming from the recent successes of 
the MPACT and PRODIGE clinical trials. As we only 
examined 3 years of trials reported in PubMed, and that 
too in the immediate aftermath of the MPACT trial, it 
will be interesting to follow the direction of these clinical 
studies, particularly in terms of the preferred future use of 
molecular selection.
In summary, despite many studies, the only targeted 
therapy with evidence of efficacy in late phase studies 
is erlotinib, yet the effect is so small that it has not been 
broadly adopted in routine practice. Molecularly-targeted 
therapies tested in unselected patients with pancreatic 
cancer may be effective in small subgroups, but the 
inability to predict these prior to treatment precludes their 
use currently.
STROMAL TARGETS
Tumor hypoxia, a consequence of hypoperfusion 
and desmoplasia that have become characteristic 
features of PDAC, has long been under intense scrutiny, 
particularly for approaches that improve drug efficacy by 
overcoming resistance to treatment. In fact, drugs that 
target hypoxia are of interest in therapeutic approaches 
that target the dense, poorly vascularized stroma that 
encapsulates PDAC tumor cells. The success of nab-
paclitaxel, which is thought to target SPARC (secreted 
protein-acid rich in cysteine), that is expressed by stromal 
cells, further encouraged this field of study.
However, the combination of gemcitabine and the 
hypoxia-activated pro-drug, TH-302, did not significantly 
improve OS in patients that presented with advanced 
pancreatic cancer [9.2 months (340 mg/m2), 8.7 months 
(240 mg/m2) vs 6.9 months (gemcitabine alone)] [36]. This 
highly cited article reported significant improvement in 
PFS [5.6 months (pooled combination arms) vs 3.6 months 
(gemcitabine alone)]. A randomized Phase III trial also 
showed no significant difference in OS (8.7 months vs 7.6 
months) and significant differences in PFS (5.5 months vs 
3.7 months) [37]. A Phase I dose escalation trial evaluating 
TH-302 in combination with GNP was terminated early 
as development of this drug was abandoned by the 
sponsoring company [38].
IMMUNOTHERAPY
Twenty (11%) of the clinical studies employed 
an immunotherapy, which seems to be a particularly 
promising avenue of study in patients that present with 
MPC (Table 3). A particularly interesting Phase Ib trial 
investigated an oral CCR-2 inhibitor (PF-04136309), 
a strategy aimed to target CCL2-CCR2 chemokine 
signaling that mediates tumor-associated macrophage 
recruitment, and therefore restores anti-tumor immunity 
[39]. Delivered in combination with FOLFIRINOX, this 
inhibitor achieved objective tumor responses in 16% of 
patients and local tumor control in 97% of patients.
A Phase I trial [40] investigating the clinical 
response of MPC patients to a combination of gemcitabine 
and mature dendritic cells pulsed with MHC class I/
II-restricted Wilms’ tumor 1 (Wt1) peptides, showed 
improvements in OS in patients that displayed WT1-
specific delayed-type hypersensitivity (DTH) (717 days). 
An earlier study [41] of a Wt1-based cancer vaccine 
delivered in combination with gemcitabine therapy had 
Oncotarget21622www.oncotarget.com
Table 5: Other therapies that achieved high median overall survival (OS) in patients that presented with advanced 
pancreatic cancer, ranked according to OS
OS Title Reference Patients Phase Randomization
17.6 months A human clinical trial using 
ultrasound and microbubbles 
to enhance gemcitabine 
treatment of inoperable 
pancreatic cancer
Dimcevski et 
al. J Control 
Release 2016
10 I No
16.6 months A phase I trial of gemcitabine, 
S-1 and LV combination 
(GSL) therapy in advanced 
pancreatic cancer
Nakai et 
al. Cancer 
Chemother 
Pharmacol 2014
15 I No
13.4 months Phase I study assessing 
the feasibility of the triple 
combination chemotherapy 
of SOXIRI (S-1/oxaliplatin/
irinotecan) in patients with 
unresectable pancreatic ductal 
adenocarcinoma
Yanagimoto 
et al. Cancer 
Chemother 
Pharmacol 2016
15 I No
13 months (conventional 
+ targeted), 7 months 
(conventional)
Combination of Two Targeted 
Medications (Bevacizumab 
Plus Cetuximab) Improve 
the Therapeutic Response of 
Pancreatic Carcinoma
Tai et al. 
Medicine 
(Baltimore) 
2016
59 retrospective
12.7 months (S, 
LDH<=UNR), 5.9 
months (S, LDH>UNR), 
8.6 months (no S, 
LDH<=UNR, 5.2 months 
(no S, LDH>UNR)
The value of lactate 
dehydrogenase serum levels 
as a prognostic and predictive 
factor for advanced pancreatic 
cancer patients receiving 
sorafenib
Faloppi et al. 
Oncotarget 
2015
71 retrospective
12.6 months first line First-in-man phase 1 clinical 
trial of gene therapy for 
advanced pancreatic cancer: 
safety, biodistribution, and 
preliminary clinical findings
Buscail et al. 
Mol Ther 2015
22 I No
12.6 months all patients, 
10.1 months MPC
The combination of a 
chemotherapy doublet 
(gemcitabine and 
capecitabine) with 
a biological doublet 
(bevacizumab and erlotinib) 
in patients with advanced 
pancreatic adenocarcinoma 
The results of a phase I/II 
study
Watkins et al. 
Eur J Cancer 
2014
44 I/II No
8.9 months all patients, 
12.4 months (1st line), 5.9 
months (2nd line)
Phase II study of capecitabine 
and the oral mTOR inhibitor 
everolimus in patients with 
advanced pancreatic cancer
Kordes et 
al. Cancer 
Chemother 
Pharmacol 2015
31 II No
MPC indicates metastatic pancreatic cancer, LDH indicates lactate dehydrogenase, UNR indicates upper normal rate.
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reported an OS of 10.9 months in DTH positive LAPC/
MPC patients, compared to 3.9 months in DTH negative 
patients. Another Japanese Phase I [42] study of the same 
therapy in LAPC and MPC patients reported an OS of 243 
days.
As with other cancer types, there has been 
considerable interest in the development and validation of 
cancer vaccines. An investigation of a mutant Ras peptide 
vaccine delivered in combination with interleukin-2 
(Arm 1) or granulocyte-macrophase colony-stimulating 
factor (GM-CSF) (Arm 2) or both (Arm 3) to enhance the 
vaccine immune response, achieved an OS of 16.6 months 
in 53 advanced cancer patients (including 11 pancreatic 
cancer patients) with no significant difference between 
arms [43].
GVAX, GM-CSF-secreting whole allogeneic 
pancreatic cancer cells, is often delivered in combination 
with cyclophosphamide (Cy), which inhibits regulatory 
T-cells. The addition of Listeria monocytogenes organisms 
expressing mesothelin (CRS-207), another cancer 
vaccine that induces innate and adaptive immunity, to 
Cy/GVAX extended OS from 3.9 months to 6.1 months 
[44]. The majority of patients (97%) had received prior 
chemotherapy and 51% had received more than two 
regimens. In a subsequent Phase IIb trial, conducted in 
patients that had failed at least two prior therapies in the 
metastatic setting, this combination failed to meet the 
primary endpoint of an improvement in OS [3.8 months 
(GVAX/Cy/CRS-207) vs 5.4 months (CRS-207 alone) vs 
4.6 months (chemotherapy)] [45].
Another vaccine of interest is GV1001, made up 
of telomerase peptides, designed to train the immune 
system to recognize this common cell surface protein. 
GM-CSF is commonly administered to patients prior 
to GV1001 therapy to boost effectiveness. A Phase III 
trial to assess GV1001 in combination with gemcitabine 
and capecitabine, failed to significantly improve overall 
survival in LAPC or MPC patients [46]. Patients received 
the gemcitabine/capecitabine combination with sequential 
GM-CSF/GV1001 (OS: 6.9 months), concurrent GM-CSF/
GV1001 (OS: 8.4 months), or alone (OS: 7.9 months).
In summary, although most single agent 
immunotherapeutic strategies in pancreatic cancer 
have been disappointing, novel combinations, based on 
preclinical evidence of efficacy [47] are being explored.
RADIOTHERAPY
Radiotherapy was utilized in 32 studies (18%), 30 
(17%) of which also employed a chemotherapy. Twenty 
(11%) studies that employed a radiotherapy also employed 
a gemcitabine-based therapy, 20 (11%) employed a 
fluoropyrimidine-based therapy and 11 (6%) employed 
capecitabine. In the highly cited LAP07 clinical trial 
[48], 442 LAPC patients were first randomized to receive 
4 months of induction chemotherapy with gemcitabine 
alone or the gemcitabine/erlotinib combination. The 
269 patients that showed progression-free disease at 4 
months were then randomized to receive 2 more months 
of the same chemotherapy with or without the addition of 
capecitabine-based radiotherapy. There was no significant 
difference in the OS achieved in patients receiving 
chemotherapy (16.5 months) vs chemoradiation (15.2 
months) and no significant difference between patients 
receiving the gemcitabine/erlotinib combination (11.9 
months) when compared to patients receiving gemcitabine 
monotherapy (13.6 months).
The case for pursuing multimodal therapeutic 
strategies in pancreatic cancer is particularly supported by 
the fact that 7 of the 8 studies that reported the highest OS 
in LAPC patients employed some form of radiotherapy 
(Table 4), with the hope that this would result in a 
downgrading of the tumor, enabling curative resection.
Six studies (3%) explored stereotactic body 
radiation therapy (SBRT). SBRT involves precise mapping 
of the tumor using imaging strategies, enabling high dose 
radiotherapy to be delivered directly to the tumor, typically 
at multiple radiation beam angles. This ablative strategy 
is attractive as biologically potent doses of radiation can 
be delivered to a localized tumor while sparing healthy 
tissue, hopefully resulting in greater efficacy with fewer 
side effects. All 6 articles that utilized SBRT did so in the 
LAPC setting. Survival was measured in 5 of these studies, 
and an OS of 18+ months was achieved in 4 (2%) studies 
with low toxicities [49–52]. Again, a study that compared 
SBRT (OS: 18.8 months) to traditional chemoradiation 
(OS: 13.6 months) found the difference in OS to be not 
significant [52], which was attributed by the authors to 
a small patient population. Four studies that employed a 
chemotherapeutic, used a gemcitabine-based therapeutic. 
The mFOLFIRINOX/SBRT multimodality combination 
is currently under investigation in a Phase III trial at 
Stanford University [53]. It will be interesting to see how 
further refinements to SBRT-based chemoradiation impact 
survival outcomes.
In summary, similar to other treatment options, 
radiotherapy is likely effective in subgroups of patients 
that are currently not predictable ahead of treatment.
ALTERNATIVE MODALITIES
Clinical trials that have evaluated alternative 
therapeutic modalities have been promising (Table 5). 
One Phase I/II study evaluated a second-generation 
photosensitizer (verteporfin) combined with photodynamic 
therapy (PDT) in 15 patients that presented with LAPC 
[54]. While patients included in this study received a range 
of oncological treatments before or after PDT, an OS of 8.8 
months (15.5 months after diagnosis) was reached. An OS 
of 17.6 months was achieved in a small cohort of LAPC 
and MPC patients (n=10), treated with a combination of 
gemcitabine and microbubbles under sonication [55]. The 
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combination of ultrasound and microbubbles appeared 
to enhance the efficacy of conventional chemotherapy in 
this Phase I trial without increasing frequency of adverse 
effects.
CONCLUDING REMARKS
While recent activity and advancements in the 
treatment options available to pancreatic cancer patients has 
been encouraging, it is readily evident that we are far from 
a cure. In particular, in patients that present with MPC, it 
is disheartening to see the attention that has been given to 
combinations that extend survival at the expense of quality 
of life. Rationally selected molecularly-targeted therapies 
have the potential for efficacious therapy with a low 
probability for side effects, but as PDAC is a molecularly 
heterogeneous disease, one would expect heterogeneous 
responses. Combinations of therapies that targeted EGFR 
and VEGFR appear to have resulted in increases in OS in 
clinical trials, but leave room for improvement. Concurrent 
inhibition of critical nodes appears to be a rational approach 
in achieving synergistic efficacy, but has the potential for 
synergistic toxicities. The clinical benefits of personalized 
medicine, where patients receive therapy based on their 
tumor’s molecular analysis, is currently under investigation 
[56, 57]. The feasibility of using genomic profiling 
to identify actionable molecular targets to inform the 
treatment of pancreatic cancer patients has been recently 
demonstrated [58]. In the context of molecularly-targeted 
therapy, it is likely that responses will be dictated by the 
tumor’s molecular signature. Therefore, the performance 
of molecularly-targeted therapy in clinical trials may be 
improved by employing molecular selection of patients. 
Post-hoc selection of MPC patients with low hENT1 failed 
to demonstrate the superiority of CO-101 over gemcitabine 
in this population, even though the former was rationally 
designed to be delivered to cells independently of hENT1 
[59]. Hyaluronan A is being used to select patients for a 
Phase III trial testing PEGylated recombinant human 
hyaluronidase in combination with GNP compared to 
GNP alone [60]. MPC or LAPC patients enrolling in a 
Phase II trial of gemcitabine, cisplatin with or without a 
PARP inhibitor, veliparib, or veliparib alone are required 
to provide confirmation of a BRCA1, BRCA2 or PALB2 
mutation [61]. PARP inhibitors, rucaparib and olaparib, 
are also under clinical investigation in patients that present 
with BRCA/PALB-associated MPC [62, 63]. Successes 
in such trials may pave the way for rational molecular 
screening of patients enrolling in clinical studies, but 
careful post-hoc analysis of pancreatic tumors will greatly 
advance our knowledge of underlying genetic markers 
that influence patient responses. This will hopefully result 
in more successful clinical trials and approvals based on 
molecularly-based disease indications.
The landscape of pancreatic cancer therapy has 
moved forward in the last 4-5 years, with shifts in the 
standard of care, and advances in our understanding of 
the molecular basis of the disease, which has been greatly 
informed by genome sequencing. Greater clinical trial 
participation, rational design of trials, which may include 
molecular screening of patients, and pursuit of novel 
therapeutic strategies should result in more powerful 
therapeutic options for this devastating disease.
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